Migraine Survey in Gulf Region

NCT06237062 | Terminated

• 1 other identifier: CAMG334AAE02
• Study Type: observational
• Target: 37
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this study was to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients who newly started on erenumab over 12 weeks

Conditions

Migraine

Keywords

migraine; survey; Gulf

Outcome Measures

Primary Outcomes (1)

• Mean score in the Treatment Satisfaction Questionnaire for Erenumab (TSQM) overall satisfaction scale score version 1.4

  TSQM is used to measure the Patients' self-reported satisfaction or dissatisfaction with the study treatment. The TSQM version 1.4 domain scores range from 0 to 100 with higher scores representing a higher satisfaction on that domain.

  12 weeks

Secondary Outcomes (10)

• Mean score in TSQM version 1.4 effectiveness domain

  Week 12

• Mean score in TSQM version 1.4 convenience domain

  Week 12

• Mean score in TSQM version 1.4 side effects domain

  Week 12

• Mean change from baseline in the score of HIT-6

  Baseline, Week 12

• Mean change from baseline in the score of MIDAS at week 12

  Baseline, Week 12

Study Arms (1)

adult migraine patients

adult migraine patients across the 4 Gulf Countries (UAE, Qatar, Oman and Kuwait)

Other: erenumab

Interventions

erenumab OTHER

This was an observational study, there was no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients were directed through a link to the full survey.

adult migraine patients

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Clinics in centers and hospitals treating adult migraine patients across the 4 Gulf Countries

You may qualify if:

• EM\& CM (with or without Medication Overuse Headache (MOH)) patients
• Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month prior study enrollment and baseline endpoints collection)
• Ability to receive 3 monthly doses of erenumab.
• Age more than 18 years
• Males and Females
• Allowing the patients to be stable on 1 adjunctive migraine preventive medication (if present)
• Agreed to be included in the study and signed informed consent

You may not qualify if:

• Less than 18 years
• Age at onset of Migraine more than 50 years
• Any contraindications to the start of erenumab as per label
• Refusal to sign informed consent
• Inability to participate or restricted access to the online survey
• Enrolled in an interventional migraine-related study at the time of the study enrollement

Sponsors & Collaborators

• Novartis Pharmaceuticals: lead

Related Links

• Link to study results

MeSH Terms

Conditions

Migraine Disorders

Interventions

erenumab

Condition Hierarchy (Ancestors)

Headache Disorders, Primary; Headache Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Novartis Pharmaceuticals

  Novartis Pharmaceuticals

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 24, 2024
• First Posted: February 1, 2024
• Study Start: June 5, 2024
• Primary Completion: November 18, 2024
• Study Completion: November 18, 2024
• Last Updated: November 20, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share